Drug Profile
Research programme: ERG inhibitors - OncoFusion
Alternative Names: RI-EIPLatest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator OncoFusion Therapeutics
- Class Peptidomimetics; Small molecules
- Mechanism of Action Proto-oncogene protein c-fli-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Mar 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Jun 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 07 May 2014 Research programme: ERG inhibitors - OncoFusion is available for licensing as of 07 May 2014. http://oncofusion.com/